Synmosa Biopharma Corporation

TPEX:4114 Voorraadrapport

Marktkapitalisatie: NT$15.3b

Synmosa Biopharma Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Chih-Hui Lin

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO19.5yrs
Eigendom CEO1.0%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur5.5yrs

Recente managementupdates

Recent updates

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Apr 04
Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Mar 08
If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 31
Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05
Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09
Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Analyse CEO-vergoeding

Hoe is Chih-Hui Lin's beloning veranderd ten opzichte van Synmosa Biopharma's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

NT$689m

Mar 31 2024n/an/a

NT$650m

Dec 31 2023n/an/a

NT$595m

Sep 30 2023n/an/a

NT$585m

Jun 30 2023n/an/a

NT$562m

Mar 31 2023n/an/a

NT$800m

Dec 31 2022n/an/a

NT$799m

Sep 30 2022n/an/a

NT$735m

Jun 30 2022n/an/a

NT$693m

Mar 31 2022n/an/a

NT$368m

Dec 31 2021n/an/a

NT$304m

Sep 30 2021n/an/a

NT$288m

Jun 30 2021n/an/a

NT$293m

Mar 31 2021n/an/a

NT$634m

Dec 31 2020NT$5mNT$4m

NT$638m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Chih-Hui redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de TW markt.

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Chih-Hui te vergelijken met de prestaties van het bedrijf.

CEO

Chih-Hui Lin (41 yo)

19.5yrs

Tenure

NT$4,710,000

Compensatie

Mr. Chih-Hui Lin serves as Chairman at Synmosa Biopharma Corporation and serves as its Director since May 16, 2019. He serves as President, Managerial officer and General Manager of the Synmosa Biopharma C...

Bestuursleden

NaamPositieTenureCompensatieEigendom
Chih-Hui Lin
Chairman19.5yrsNT$4.71m1.02%
NT$ 156.7m
San-Chien Tu
Additional Independent Director1.3yrsgeen gegevensgeen gegevens
Xiang-Lang Liu
Independent Director21.8yrsNT$1.07mgeen gegevens
Xiu-Mei Lin
Independent Director5.5yrsNT$1.19m0.0011%
NT$ 163.9k
You-Peng Zhang
Representative Director5.5yrsNT$1.09m1.01%
NT$ 154.6m
Li-Wen Huang
Representative Director15.8yrsNT$1.09m0.96%
NT$ 147.6m
Huilan Qiu
Independent Directorless than a yeargeen gegevens1.92%
NT$ 294.4m

5.5yrs

Gemiddelde duur

42yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4114 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).